CNTX Stock — Context Therapeutics Inc

Context Therapeutics Inc (CNTX)

Updated October 16, 2026.

CNTX is a Stock. Total return is -95.2% over the past 5 years, 175.6 points behind SPY at 80.4%.

Context Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors, with its lead candidate being CTIM-76, a bispecific antibody designed to direct immune cells against cancer cells expressing the Claudin 6 protein. The company does not currently distribute dividends. This security appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on income generation.

CNTX performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.2% over the past 5 years, 175.6 points behind SPY at 80.4%. Over the past year its total return — price change plus distributions reinvested — is -80.6%. Its deepest 1-year drawdown was 92.8%.

CNTX key facts

Asset type

Stock

Asset class

Equity

Inception date

10/20/2021

Distribution frequency

None

Last close

$0.24 (as of 2026-10-16)

Market cap

$22,418,519

Average volume

2235658.0

Beta

1.716

Payout ratio

0.0%

EPS

$-0.49

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CNTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 92.8%.

Who may consider CNTX — and who may not

It is a weaker fit for investors who need monthly cash flow (CNTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CNTX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions